Furthermore, although the development of single-cell sequencing technologies has revealed promising insights into tumor biology, understanding how these findings could be applied to LUAD is still limited, specifically in the context of resistance to PD-1/PD-L1 inhibitors. The gene discussed is CD274; the disease is neoplasm.